Trial Profile
Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms CARIN
- 23 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
- 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.